| Literature DB >> 35314846 |
Rosa Barreira da Silva1, Ricardo M Leitao2, Ximo Pechuan-Jorge2, Scott Werneke2, Jason Oeh2, Vincent Javinal2, Yingyun Wang2, Wilson Phung2, Christine Everett2, Jim Nonomiya2, David Arnott2, Cheng Lu2, Yi-Chun Hsiao2, James T Koerber2, Isidro Hötzel2, James Ziai2, Zora Modrusan2, Thomas H Pillow2, Merone Roose-Girma2, Jill M Schartner2, Mark Merchant2, Sascha Rutz2, Céline Eidenschenk2, Ira Mellman3, Matthew L Albert4,5.
Abstract
Tumor-associated macrophages are composed of distinct populations arising from monocytes or tissue macrophages, with a poorly understood link to disease pathogenesis. Here, we demonstrate that mouse monocyte migration was supported by glutaminyl-peptide cyclotransferase-like (QPCTL), an intracellular enzyme that mediates N-terminal modification of several substrates, including the monocyte chemoattractants CCL2 and CCL7, protecting them from proteolytic inactivation. Knockout of Qpctl disrupted monocyte homeostasis, attenuated tumor growth and reshaped myeloid cell infiltration, with loss of monocyte-derived populations with immunosuppressive and pro-angiogenic profiles. Antibody targeting of the receptor CSF1R, which more broadly eliminates tumor-associated macrophages, reversed tumor growth inhibition in Qpctl-/- mice and prevented lymphocyte infiltration. Modulation of QPCTL synergized with anti-PD-L1 to expand CD8+ T cells and limit tumor growth. QPCTL inhibition constitutes an effective approach for myeloid cell-targeted cancer immunotherapy.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35314846 DOI: 10.1038/s41590-022-01153-x
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 31.250